Technical Analysis for DXCM - DexCom, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 1.59% | |
| Multiple of Ten Bearish | Other | 1.59% | |
| Outside Day | Range Expansion | 1.59% | |
| NR7 | Range Contraction | -0.51% | |
| NR7-2 | Range Contraction | -0.51% | |
| Narrow Range Bar | Range Contraction | -0.51% | |
| Multiple of Ten Bullish | Other | -0.51% | |
| Up 3 Days in a Row | Strength | -0.51% | |
| Up 4 Days in a Row | Strength | -0.51% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.16% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 2 hours ago |
| Rose Above 10 DMA | about 2 hours ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 2 hours ago |
| Down 2 % | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/25/2024
DexCom, Inc. Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments. The company's in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. The company markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: S&P 500 Medicine Nasdaq 100 Diabetes Telehealth Telemedicine Healthcare Providers Software Platform Glucose Endocrine System Platinum Diabetes Mellitus Medical Monitoring Blood Glucose Monitoring Endocrinology Continuous Glucose Monitor Hyperglycemia Glucose Monitoring Systems Hypoglycemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 142.0 |
| 52 Week Low | 74.75 |
| Average Volume | 2,967,531 |
| 200-Day Moving Average | 114.85 |
| 50-Day Moving Average | 132.45 |
| 20-Day Moving Average | 131.64 |
| 10-Day Moving Average | 128.36 |
| Average True Range | 4.18 |
| RSI (14) | 43.18 |
| ADX | 22.75 |
| +DI | 14.70 |
| -DI | 25.44 |
| Chandelier Exit (Long, 3 ATRs) | 129.44 |
| Chandelier Exit (Short, 3 ATRs) | 135.62 |
| Upper Bollinger Bands | 140.72 |
| Lower Bollinger Band | 122.55 |
| Percent B (%b) | 0.27 |
| BandWidth | 13.80 |
| MACD Line | -1.65 |
| MACD Signal Line | -1.17 |
| MACD Histogram | -0.4758 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 132.40 | ||||
| Resistance 3 (R3) | 132.83 | 131.59 | 131.57 | ||
| Resistance 2 (R2) | 131.59 | 130.33 | 131.38 | 131.29 | |
| Resistance 1 (R1) | 129.51 | 129.54 | 128.89 | 129.08 | 131.02 |
| Pivot Point | 128.27 | 128.27 | 127.97 | 128.06 | 128.27 |
| Support 1 (S1) | 126.19 | 127.01 | 125.57 | 125.76 | 123.82 |
| Support 2 (S2) | 124.95 | 126.22 | 124.74 | 123.55 | |
| Support 3 (S3) | 122.87 | 124.95 | 123.27 | ||
| Support 4 (S4) | 122.44 |
